Ladenburg Thalmann Financial Services’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-267	Closed	-$3K	–	5450
2018 Q4	$3K	Buy	+267	New	+$3.88K	﹤0.01%	4839
2018 Q3	–	Sell	-1,533	Closed	-$46K	–	5423
2018 Q2	$46K	Hold	1,533	–	–	﹤0.01%	3318
2018 Q1	$46K	Hold	1,533	–	–	﹤0.01%	3318
2017 Q4	$59K	Hold	1,533	–	–	﹤0.01%	3115
2017 Q3	$33K	Hold	1,533	–	–	﹤0.01%	3383
2017 Q2	$31K	Buy	+1,533	New	+$31.7K	﹤0.01%	3345

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BLPH Position: Q1 2019 in Review

Ladenburg Thalmann Financial Services sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2019, closing a stake of 267 shares — an estimated $3K sold.

Ladenburg Thalmann Financial Services first reported a position in BLPH in Q2 2017 and held it in 6 quarters. The position peaked at $59K in Q4 2017. 26 funds tracked by Wall St. Rank hold BLPH as of Q1 2019.

Ladenburg Thalmann Financial Services reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 267 Bellerophon Therapeutics, Inc. shares in Q1 2019, an estimated $3K.
Ladenburg Thalmann Financial Services first reported a position in Bellerophon Therapeutics, Inc. in Q2 2017 and held it in 6 quarters.
Ladenburg Thalmann Financial Services's Bellerophon Therapeutics, Inc. position peaked at $59K in Q4 2017.
26 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2019, filed 15 May 2019.